Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of MU-MA402C for MAGE A4-positive, HLA-A*02:01-positive unresectable solid tumors
jRCT2043210077Phase 1Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Nov 2021
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MU-MA402C in Nonhematologic neoplasms and Not applicable (2 cohorts), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Safety and tolerability of MU-MA402C. Started Nov 2021; status: active, not recruiting.
02
Drugs
MU-MA402C
03
Conditions
Nonhematologic neoplasmsNot applicable
Beyond the preview
Go deeper on jRCT2043210077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2043210077.